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Abstract
Similar to human CLL, the de novo NZB mouse model has a genetically determined age-
associated increase in malignant B-1 clones and decreased expression of microRNAs miR-15a and 
miR-16 in B-1 cells. In the present study, lentiviral vectors were employed in vivo to restore 
miR-15a/16, and both the short-term single injection and long-term multiple injection effects of 
this delivery were observed in NZB. Control lentivirus without the mir-15a/16 sequence was used 
for comparison. We found that in vivo lentiviral delivery of mir-15a/16 increased miR-15a/16 
expression in cells that were transduced (detected by GFP expression) and sera when compared to 
control lentivirus treatment. More importantly, mice treated with the miR- expressing lentivirus 
had decreased disease. The lentivirus had little systemic toxicity while preferentially targeting B-1 
cells. Short-term effects on B-1 cells were direct effects and only malignant B-1 cells transduced 
with miR-15a/16 lentivirus had decreased viability. In contrast, long-term studies suggested both 
direct and indirect effects resulting from miR-15a/16 lentivirus treatment. A decrease in B-1 cells 
was found in both the transduced and non-transduced populations. Our data support the potential 
use of systemic lentiviral delivery of miR-15a/16 to ameliorate disease manifestations of CLL.
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Introduction
Chronic lymphocytic leukemia (CLL), the most common leukemia to affect adults in the 
Western world, is an age-associated malignancy characterized by the expansion of CD5+ 
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B-1 cells (1). Over 50% of CLL patients have a deletion within the 13q14 chromosomal 
region (2) containing the DLEU2 gene (3, 4), a non-coding RNA which contains the 
microRNA locus for mir-15a/16-1 within an intronic region (5). MicroRNAs (miRNAs) are 
small, evolutionarily conserved, non-coding single-stranded RNAs that regulate gene 
expression by binding with an RNA-Induced Silencing Complex (RISC complex) to the 3′ 
untranslated region (UTR) of target mRNA (6–8). Mutations and alterations, resulting in the 
loss or amplification of miRNAs affect the regulation of cell cycle and survival mechanisms, 
and have been linked to many human cancers and leukemias (5, 9–12). Many miRNAs were 
found to be located within genomic ‘fragile sites’ associated with malignant transformation 
such as regions of amplification, deletion, loss of heterozygosity, and breakpoint regions 
near oncogenes and tumor suppressor genes. (13, 14). miRNAs mir-15a and mir-16-1 are 
located in the frequently deleted 13q14 region, and are also associated with decreased levels 
of mature miR-15a and miR-16 in a subpopulation of patients with B cell chronic 
lymphocytic leukemia (B-CLL) (15, 16).
The New Zealand Black (NZB) mouse, in contrast to all other available CLL murine 
models, is a de novo model for both autoimmunity (17) and CLL (18, 19). Similar to CLL, 
the NZB develop an age-associated expansion of polyreactive, CD5 expressing, malignant 
B-1 cells, with clones often possessing chromosomal abnormalities resulting in aneuploidy 
(18–21). At 9 mo of age, all NZB mice have expanded B-1 populations, however, 
approximately 10% of the NZB mice that live beyond 17 months of age develop T cell 
clones with elevated IFN gamma production leading to an eventual decrease in B-1 cells at 
17 months of age (22). NZB mice also exhibit a T -> A germline point mutation 6 bases 
downstream from pre-mir-16-1 on chromosome 14 (23), similar to the C -> T point mutation 
reported in human CLL (24), as well as decreased miR-15a and miR-16 expression.
We have previously reported the exogenous addition of miR-15a/16 in vitro to an NZB-
derived malignant B-1 cell line to lead to a significant accumulation of cells in G1 and 
decrease in cyclin D1 protein levels (25). In this report, mir-15a/16-1 was systemically 
delivered to NZB mice with CLL via in vivo lentiviral delivery of a vector expressing both 
GFP and the wild-type mir-15a/16-1 sequence (mir-15a/16). We proposed that restoration of 
miR-15a/16 to malignant B cells in vivo would have similar effects as in vitro, particularly 
growth arrest and eventual death, resulting in disease reduction. Because transduced 
malignant B-1 cells were found to secrete the exogenously-delivered microRNA into the 
circulation, a subpopulation of lentivirus-injected NZB mice were re-injected at Day 24 [a 
time approaching the half-life of lymphoyctes (26)] and analyzed 4 days later to increase the 
likelihood of finding viable GFP+ cells. The peritoneum, spleen, blood, and liver of treated 
mice were evaluated 8–9 days (single injection, short-term) and 28–29 days (two injections, 
long-term) post-injection for the presence of malignant B-1 clones, the extent of organ 
involvement, and toxicity. Lentiviral delivery of mir-15a/16-1 to NZB mice resulted in a 
reduction of malignant B-1 cells and decreased splenic and hepatic involvement. Our data 
support the potential use of systemic lentiviral delivery of miR-15a/16 to ameliorate disease 
manifestations of CLL.
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Methods
Mice
NZB/BlNJ, C57Bl/6J, and DBA/2J were purchased from Jackson Laboratory (Bar Harbor, 
ME) and housed under standard pathogen-free conditions at the research animal facility at 
UMDNJ – New Jersey Medical School, Newark, NJ. All non-NZB strains were used as 
control strains that do not develop CLL disease.
In vivo lentiviral delivery of miR-15a/16
Aged NZB mice (9–17mo) with disease were injected with lentivirus containing either a 
control GFP-expressing vector (control-lenti,) or a GFP and mir-15a/16-1 expressing vector 
(mir-lenti,). Four separate in vivo experiments were performed. For the first two 
experiments (terminated on Day 8–9 post single injection and Day 28 post two injections) 
the lentiviruses containing the mir-15a/16 loci and GFP or solely GFP were generated as 
previously described (27). The lentivirus was introduced iv for a systemic effect and ip for a 
local effect since the target B-1 cells in NZB mice are located in the blood, peritoneum and 
spleen. NZB mice were injected (ip.) with 100ul and i (i.p.) with 100ul lentivirus solution, 
containing 1×108 TU in media, 4ug/ml polybrene, and 1× PBS. Mice were either sacrificed 
at 8 and 9 days post-injection (control n=5, mir-15a/16, n=8), or mice were re-injected i.p. 
on day 24, and sacrificed at 28 and 29 days post-initial-injection (control n=4, mir-15a/16, 
n=4). In the third repeat experiment, NZB mice (9mo) were injected with lentiviral 
constructs containing the microRNAs miR15a/16 and GFP obtained from Systems 
Biosciences (SBI, Mountain View, CA, USA) and the packaging vectors were obtained from 
Addgene (Cambridge, MA, USA)). Mice were injected ip with 100ul and iv with 100ul 
lentivirus solution, containing 5×107 TU in media, 4ug/ml polybrene, and 1× PBS. Mice 
were sacrificed at 8 days post-injection (control-lenti n=3, mir-15a/16, n=3). The fourth 
repeat experiment was performed with the same SBI lentiviruses injection sites, doses and 
duration as for the third experiment with the exception that the NZB mice were all 12 
months of age (control-lenti n=4, mir-15a/16, n=4). Mice were terminally bled prior to 
euthanasia and animal and spleen weight determined. For sera levels of microRNAs, EDTA 
was employed as an anticoagulant.
Detection of B-1 cells via flow cytometry
For identification of malignant B-1 cells, single-cell suspensions were made from spleen, 
peritoneal wash cells (PWC), and red blood cell lysed peripheral blood (PB) and surface 
stained with anti-mouse IgM allophycocyanin (APC, Caltag Invitrogen) and anti-mouse 
CD5 phycoerythrin (PE, Caltag, Invitrogen) and in some cases anti-CD5-APC, anti-B220-
PE-Cy7 (RA36B2 clone) both from Becton Dickinson. Twenty-thousand events were 
acquired on a FACSCalibur and data was analyzed using CELLQUEST software (Becton 
Dickinson).
Analysis of DNA content
Cells from spleens, PWC, and PB were stained with hypotonic PI (0.05mg/ml PI, 0.1% 
Triton X-100, 0.1% sodium citrate) at time of sacrifice and acquired on Becton Dickinson 
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FACSCalibur using CELLQUEST software (Becton Dickinson) and analyzed using ModFit 
LT V3.1 software (Verity Software House).
Cell sorting
Cells from spleens of NZB injected with either control-GFP lentivirus (control) or 
miR-15a/16-GFP-expressing lentivirus (mir-15a/16) were stained with IgM PE. Cells were 
then sorted on a FACSVantage (Becton Dickinson) on the basis of their GFP and IgM 
expression into GFP+/IgM+ and GFP−/IgM+ populations. In additional sorts, cells were 
stained with anti-CD5-PE and anti-B220-PE/Cy5 and sorted into transduced and non-
transduced B-1 or B-2 cells (GFP+/ B220dull/CD5dull = transduced B-1, GFP−/ 
B220dull/CD5dull = non-transduced B-1, GFP+/ B220+/CD5− = transduced B-2, GFP−/ 
B220+/CD5− = non-transduced B-2)
MicroRNA extraction and quantification
Total RNA, including miRNA, was extracted from sorted splenic cells according to the 
Trizol (Invitrogen) manufacturer’s protocol. Quantitative real time PCR (qPCR) was used to 
quantitate mature miR-16 expression in sorted cells using the TaqMan microRNA Reverse 
Transcription and TaqMan miRNA hsa-miR-16 Assay Kit (Applied Biosystems, Foster 
City, CA). The qPCR reaction was run on the Applied Biosystems 7500 Real-Time PCR 
Systems for 40 cycles at 60°C. The miR-16 relative quantification (RQ) values of GFP+ 
cells from control-treated NZB compared to miR-16 from cells of miR-16-treated NZB were 
determined using the standard 2−ΔΔ CT method according to the manufacturer’s protocol. 
The total amount of input RNA was normalized to Taqman U6 snRNA (Applied 
Biosystems). Circulating levels of microRNA were performed by analysis of 20 μl of plasma 
(EDTA) from individual NZB mice 9 mo of age (control-lenti or mIR-15a/16 groups, n=3) 
obtained 8 days post in vivo lentivirus injection. Plasma was diluted to a final volume of 200 
ul in RNase-free water and TRIzol® LS Reagent (Life Technologies) RNA isolation method 
was followed as per manufacturer’s instructions. The final RNA pellet was resuspended in 
20 μl of RNase-free water and subsequently reverse transcribed (TaqMan Universal PCR 
Master Mix No AmpErase®UNG, Applied Biosystems), followed by TaqMan®MicroRNA 
quantitative RTPCR for miR15a and miR30c (endogenous control). Individual RQ values 
were generated in triplicate and then the group average RQ determined and graphed.
Histopathology
Formalin-fixed tissue sections of liver and spleen from control and TW-mir-15a/16 NZB 
mice were stained with hematoxylin and eosin and analyzed using an Olympus BX40 
microscope with 10x, 20x and 40x objective lenses. Digital images were taken.
Liver chemistry
Sera and plasma collected in heparinized tubes were analyzed by Ani Lytics Inc. 
(Gaithersburg, MD) for aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), bilirubin, and albumin levels. Untreated NZB (11–12 mo and 
17mo) were used as noninjected controls.
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Statistical analysis
All experiments performed were at least in triplicate to obtain standard deviations and to 
calculate the SEM. Student’s t test was used where appropriate to determine statistical 
significance, p ≤ 0.05.
Results
NZB as a de novo model for chronic lymphocytic leukemia
The New Zealand Black (NZB) mouse model is a de novo model of CLL (18). Similar to 
CLL, and in contrast to other normal strain mice, NZB mice develop a malignant expansion 
of hyperdiploid IgM+ CD5dull B220 dull CD11b dull B-1 clones with age (19, 21, 28). 
Spleens were isolated from NZB mice at different ages: young (1–6 months), mid-aged (6–
10 months) and old (11–15 months), (at least 3 mice per group), and compared to normal 
strain mice. Splenic single cell suspensions were then analyzed for DNA content and for the 
presence of IgM+ CD5dull B220 dull B-1 cells. Flow cytometric analysis revealed a lack of 
hyperdiploidy and minimal presence of an IgM+ CD5dull B-1 population in the spleens of 
normal non-NZB strain mice (Figure 1A) and of young NZB mice (Figure 1B). However, 
NZB mice were shown to develop an expansion of hyperdiploid B-1 clones with age (IgM+ 
CD5dull B220 dull, only IgM and CD5 expression shown). The disease in most cases 
progresses from a pauciclonal state (see middle panel with two hyperdiploid peaks) to CLL 
with a single dominant clone characterized as IgM+CD5dull B220 dull (Figure 1B). Middle-
aged NZB mice exhibit multiple malignant hyperdiploid clones, as seen in reported cases of 
Monoclonal B-cell Lymphocytosis (MBL) (29) (Figure 1B), demonstrating a precursor state 
to the development of CLL in old NZB. Aging NZB spleens had significantly higher levels 
of B-1 cells when compared to the spleen cells from age-matched non-NZB normal strain 
mice (Figure 1C). In addition to an expansion of hyperdiploid malignant B-1 clones, NZB 
mice also possess a germline point mutation in the mir-15a/16-1 locus on chromosome 14 
(23), similar to the point mutation reported in a CLL patient (24). This mutation is correlated 
with a decrease in mature miR-16 levels in the spleen (23). Levels of miR-16 were measured 
in the spleens of NZB mice at the aforementioned ages and compared to age-matched non-
NZB normal strain mice with wild-type mir-15a/16-1. At all ages, NZB are found to have a 
decrease in miR-16 levels when compared to age-matched non-NZB mice, with significantly 
lower levels in young and old NZB mice (Figure 1D). The miR-16 levels in NZB seem to be 
constant throughout their lifetime; however, levels in non-NZB strain mice seem to fluctuate 
throughout the aging process, although remaining higher than levels in the NZB (Figure 
1D). Subsequent experiments were carried out using middle-aged and old NZB mice with 
disease.
In vivo analysis of cells transduced with mir-15a/16 lentivirus have increased miR-16 
production
Aged NZB mice with disease were injected with lentivirus containing either a control GFP-
expressing vector (control-lenti) or a GFP and mir-15a/16-1 expressing vector (mir--lenti). 
Mice were sacrificed at 8–9 days (short-term) after the initial injection and analyzed for 
miR-16 levels, B-1 number, % of transduced cells and apoptosis. The post 8–9 timepoint for 
study was based on our observation that in the NZB B cell line, delivery of the lentivirus in 
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vitro led to apoptosis in 3 days (25) and in vivo injection most likely would take longer for 
the lentivirus to circulate, enter the tissue, bind to the cell, integrate and express. Sera was 
analyzed for the levels of miR-16 by realtime PCR and sera obtained from NZB mice 
injected with lentivirus containing the mir-15a/16 loci had significantly elevated levels of 
miR-16 (Fig 2A) compared to sera from the control lentivirus injected NZB. Spleens from 
lentivirus injected NZB were analyzed for GFP and surface marker expression and sorted 
into both B-1 and B-2 transduced and non-transduced cells (representative sorts shown in 
Fig 2D control-lenti and Fig 2E mir-lenti mice). The sorted GFP+ B-1 cells from the spleens 
of miR-lenti treated mice had significantly elevated miR-16 levels when compared to the 
miR-16 levels in the GFP+ B-1 cells from the control-lenti treated group (Fig 2B). PWC 
were also analyzed for the presence of GFP+ cells, and similar to the spleen, the B-1 cells 
preferentially expressed GFP relative to B-2 cells or non-B cells (Supplemental Figure 1). 
Overall, there was a decrease in total B-1 percentages in the spleens of mice injected with 
miR-lentivirus compared to the B-1 percentage in control-lenti spleens (Fig 2C). 
Furthermore, analysis of the lenti-virus treated mice compared to uninjected NZB 
demonstrated a significant decrease in splenic B-1 cells only in the mir-15a/16-lenti treated 
group (Supplemental Fig 2). Percentages of total live cells (R1 gate, Figures 3A and 4A) 
were analyzed from mice injected with mir-15a/16 lentivirus compared to control-lenti. Live 
cells were then gated on GFP and further analyzed for IgM and CD5 expression (Figures 3B 
and 4B). (The majority of GFP+ cells were also IgM+, 93.7% ± 1.07 (short-term mice) and 
97.7% ± 1.36 (long-term mice)). The percentage of live GFP+ B-1 (IgM+/CD5+/dull) in the 
spleen, PWC, and PB decreased in short-term NZB injected with mir-15a/16-lenti (Figure 
3B, C,) when compared to control-lenti. Over a 40% decrease in GFP+ B-1 (IgM+/
CD5+/dull) in the spleen and PWC was detected in long-term NZB injected with mir-15a/16-
lenti (Figure 4C) when compared to NZB injected with control lentivirus. Unexpectedly, an 
increase in the percentage of GFP+ B-1 cells was seen in the PB (Figure 4C), although this 
may be due to a splenic flush.
The percentage of GFP+ B-1 cells was also analyzed in the apoptotic gate (R2 gate Figures 
3A and 4A). The percentage of apoptotic GFP+ B-1 cells was compared to the percentage of 
live GFP+ B-1 cells. The short-term NZB injected with mir-15a/16-lenti had a higher ratio of 
apoptotic to live GFP+ B-1 cells, particularly in the PWC (Figure 3D). This suggests that 
B-1 cells that picked up the miR-15a/16-expressing lentivirus underwent more apoptosis 
than in the same population in control-lenti treated NZB. The long-term NZB injected with 
mir-15a/16-lenti had a higher ratio of apoptotic to live GFP+ B-1 cells in the PWC and 
spleen (Figure 4D).
Genomic instability is a feature of CLL(30) and NZB mice demonstrate progressive 
aneuploidy in the B-1 clones as they age (31). A decrease in the overall presence of 
malignant aneuploid cells was detected from long-term NZB injected with mir-15a/16-lenti 
when compared to NZB treated with control empty vector (Supplement Fig 2).
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Histopathological analysis of NZB treated with miR-15a/16 lentivirus indicates decreased 
disease
Histopathological analysis of short-term treated NZB mice found that three of the four 
control Tween-treated NZB exhibited bulk disease in the spleen, with malignant lymphoid 
cells (characterized by a dark, compact nucleus and scant cytoplasm) invading both red and 
white pulp, resulting in the total loss of splenic architecture. Four of five mice treated with 
TW-miR-15a/16 exhibited a decrease in splenic involvement. Less malignant lymphoid cells 
were present, and splenic architecture (red/white pulp and germinal centers) was more 
defined in the miR-15a/16 treated mice. Three of the four mice treated with control 
lentivirus exhibited liver involvement of endogenous disease, marked by large foci forming 
around the blood vessels in the liver. Four of the five mice treated with miR-15a/16 
exhibited a decrease in liver involvement, with a marked decrease in foci by the blood 
vessels. Representative histology is shown in Figure 5.
Lack of toxicity following lentiviral delivery of miR-15a/16
Animal weight and liver function were analyzed in lentivirus treated animals. The following 
functional liver enzymes were measured in the serum or plasma of lentiviral treated and 
untreated NZB: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), bilirubin, and albumin. AST and ALT are involved in catabolizing 
amino acids, and ALP in bile production. Bilirubin is the resulting product of hemolysis and 
is excreted in bile, and albumin is a protein made by the liver. Abnormal levels of liver 
enzymes are indicative of improper liver function and damage. Injury to the liver can cause 
hepatocytes to release their enzymes into the bloodstream, thereby raising serum 
concentrations of AST and ALT, for example (32). NZB have naturally low levels of ALT, 
which remained consistent throughout treatment with either the control Tween lentiviral 
vector or miR-15a/16 vector (TW-mir-15a/16). AST levels remained within normal range 
throughout short-term treatment; however, AST levels elevated slightly above normal in 
long-term NZB treated with the mir-15a/16 lentiviral vector, though this increase was not 
significant. ALP levels were low after treatment with either control vector or mir15a/16-lenti 
(Figure 6A). Bilirubin levels were normal after treatment with either control- lenti or 
mir15a/16 lentiviral vector for both short-term and long-term mice. Likewise animal weight 
was similar in both lenti-treatment groups and not different from untreated NZB. Albumin 
levels were slightly lower than normal in the short-term control vector treated mice and in 
the long-term control vector and miR-15a/16 treated mice (Figure 6B).
Discussion
In this report we employed the NZB mouse model of CLL, which similar to human CLL, 
have an age-associated increase in malignant B-1 clones and decreased expression of 
miR-15a/16 in B-1 cells. We found that in vivo lentiviral delivery of miR-15a/16 
significantly increased miR-15a/16 expression in cells that were transduced (GFP+) and 
significantly increased the serum levels of miR-16. More importantly, mice treated with the 
miR-expressing lentivirus had decreased disease. The lentivirus had little systemic toxicity 
while preferentially targeting B-1 cells as evidenced by decreased proliferation and 
increased apoptosis in these cells. Previously published reports have supported the 
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therapeutic uses of miRNAs in cancers and other diseases using tumor cell lines and 
xenograft animal models. Non-viral and viral delivery methods of a deficient miRNA to 
cancer models and cell lines has been shown to reduce malignancy and tumor load in 
xenograft models (33–36). Reconstitution of miR-15a/16 expression also resulted in a 
reduction in prostate tumors engrafted into a mouse model for prostate cancer (27). These 
models restore miRNA levels in vitro to tumor cell lines that are then transplanted into 
immuno-compromised animal models or deliver virus directly into tumor mass, 
demonstrating the lack of ability of the miRNA-reconstituted malignant cells to form bulky 
tumors. Few have reported systemic delivery of miRNA, either in the form of synthetic 
mimics (37) or produced and delivered virally, and shown to be effective and well-tolerated 
(36, 38). In this report, we demonstrate the effects of systemically restoring miR-15a/16 in 
vivo to a naturally-diseased mouse model, the NZB mouse model of CLL, and that this 
restoration is also both effective and well-tolerated. Lentiviral vectors are advantageous in 
treatment of CLL in that they transduce non-dividing cells and hematopoietic cells (39, 40). 
Integrase-defective lentiviral vectors are viewed to be less hazardous in that they do not 
integrate into the host genome (41). These vectors can also be used in CLL therapy in that 
once miR-15a/16 is delivered to the deficient malignant cells, their proliferation is ceased or 
they undergo apoptosis and replication of the lentivirus is not needed. Aside from being used 
as diagnostic and prognostic markers (42), miRNAs also have potential therapeutic uses, as 
supported by our present data. Restoration of miR-15a/16 has also been shown to enhance 
drug sensitivity of malignant cells while having little to no effect on normal cells (25), 
further supporting the use of miR-15a/16 delivery as potential therapeutic use for CLL.
The most recently engineered mouse model of CLL demonstrates that a lack of mir-15a/
16-1 leads to development of a B-1 cell proliferative disorder (43). Our data show that in 
vivo restoration of miR-15a/16, delivered via lentivirus, to the NZB model of CLL has a 
negative effect on malignant B-1 cells. Short-term (8–9 days post single lentivirus treatment) 
and long-term (28–29 days post initial lentivirus injection) effects of endogenous 
miR-15a/16 addition were evaluated in the NZB. The overall effect of lentiviral delivery of 
miR15a/16, was an increase in level of these microRNAs in the sera and a decrease in the 
percentage of B-1 cells. The variability in the efficiency of transduction and the inherent 
variability between mice diminishes the statistical significance between the control-lenti and 
miR-lenti treated groups. Despite this, repeat experiments also supported the conclusion that 
B-1 cell number is decreased in the miR-lenti treated group and the decrease in B-1 cells 
was statistically significant. Evaluation of long-term mice treated with mir-15a/16 lentivirus 
exhibited a decrease in aneuploid cells in the PWC, spleen and PB when compared to those 
injected with the control lentivirus. In order for miR-15a/16 restoration to result in a 
decrease in the total percentage of aneuploid malignant B-1 cells, longer than a week’s time 
is required and/or multiple injections of miRNA are needed. This report demonstrates the 
potential therapeutic value of restoring miR-15a/16 levels in CLL. However, these are initial 
studies and many unanswered questions remain. Formal pharmacokinetics need to be 
established and the effect of sustained elevation of miR-15a/16 levels in vivo over time in 
the NZB analyzed. The ultimate goal of miR-15a/16 restoration would be a significant 
increase in lifespan despite the initial presence of CLL. Although these present studies are 
preliminary, there is a preferential uptake of the lentivirus into B-1 cells.
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The malignant cells in both the NZB and in human CLL are IgM+/CD5+/dull B-1 cells. The 
percentage of live B-1 cells was evaluated in the control and miR-15a/16 treated mice. The 
percentage of live B-1 cells that integrated the mir-15a/16 lentivirus (GFP+/IgM+/CD5+/dull) 
was decreased in both short and long term groups. Evaluation of GFP+ B-1 cells in short 
term treatment revealed a decrease of greater than 40% in the spleen, PWC and blood of 
mir-15a/16-lenti injected NZB compared to the percentage of live GFP+ B-1 cells in the 
control NZB.
Long-term effects of the lentivirus also revealed a decrease in GFP+ B-1 cells in the PWC 
and spleen. The spleen had only trace amounts of GFP+ apoptotic cells, suggesting that the 
immune system may have cleared the dead cells in the spleen prior to evaluation of the long-
term mice. The PWC and spleen of mir-15a/16-lenti injected NZB had more dead GFP+ B-1 
cells (a higher ratio in the percentage of apoptotic to live GFP+ B-1 cells), suggesting that 
elevation of miR-15a/16 specifically kills malignant B-1 cells. The blood, however, did not 
show a decrease, suggesting that perhaps the surviving malignant B-1 cells exited the spleen 
and entered the peripheral circulation.
The majority of cells that integrated the lentivirus are expressing IgM, suggesting that the 
lentivirus is preferentially incorporated by mature B cells. However, the effects of 
miR-15a/16 restoration leads to cell death preferentially in B-1 cells. The long-term treated 
mice exhibited a decrease in live B-1 cells regardless of whether the cells incorporated the 
miR-expressing lentivirus, suggesting an indirect effect on the remaining malignant B-1 
cells. This indirect effect could be the secretion of miR-15a/16 either directly in the 
extracellular environment, via cell-cell interactions or via exosomes containing the miRNAs 
(44) to cells that did not incorporate the miR-15a/16-expressing lentivirus. Recent reports 
have shown that exosomes play important roles in intercellular communication. These cargo 
containing nano-vesicles (30–100 nm) are secreted by numerous cell types and proteomic 
studies have shown that they harbor an abundance of micro RNAs, mRNAs and proteins 
characteristic of their particular cellular origin (reviewed in (45)). Several reports have 
shown that secreted exosomes can act as important vehicles to horizontally transfer 
biological information to another cell (46, 47). This recently identified mechanism of 
exosome mediated cell-cell transfer has been shown to activate cell signaling mechanisms as 
well as exert immunomodulatory influences on surrounding cells (reviewed in (48)). Indeed, 
in CLL there is evidence for the increased presence of microvesicles in the serum when 
compared to control individuals(49). In this report the lenti-viral transduced NZB B cells 
may potentially release miR15a/16-1 enriched exosomes that are taken up by other cells. 
This in turn, could contribute to a more robust effect than what can be accounted for by 
miR15a/16-1 lenti-viral transduced cells only. Alternatively, the decrease in GFP- B-1 cells 
may be due to a decrease in supporting cells (perhaps Bregs, Tregs, or other B-1 cells) 
which have picked up the lentivirus and have reduced proliferation and/or production of 
growth factors (perhaps IL-10) which aid in the in vivo expansion of the malignant B-1 
clone (See Fig 7). The finding of reduced growth of malignant B-1 cells in NZB mice 
treated in vivo with a lentivirus, which can integrate and lead to increased miR-15a/16 
expression, is consistent with our reported in vitro results (25). This data suggests that 
lentiviral miR-15a/16 restoration does have a negative effect on the cells into which it 
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integrates, particularly IgM+ B cells. Restoration induces apoptosis of malignant B-1 cells, 
and multiple injections may be needed to see a more pronounced effect and reduction in 
overall disease. In addition, lentiviral delivery of microRNAs may also result in indirect 
effects negatively impacting malignant cell survival by targeting cancer-supporting cells or 
by intercellular delivery of miRNAs to malignant cells.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Age-associated disease of the NZB de novo mouse model of CLL
A, Top: Representative analysis of DNA content from old (15mo) disease-free C57Bl/6 
(non-NZB) spleen. The peak represents diploid G1 (peaks shown are computer modeled). 
Bottom: Flow cytometric analysis of surface staining of non-NZB splenic cells (lymphoid 
gate) expressing IgM (x-axis) and CD5 (y-axis). B, Top: Representative analysis of DNA 
content from young (1–6mo) disease-free, middle-aged (6–10mo), and old (11–15mo) NZB 
spleens. Bottom: Flow cytometric analysis of surface staining of NZB splenic cells (from 
spleen samples above) for IgM and CD5 (arrows indicate location of malignant B-1 clones). 
C, Columns represent the percentage of IgM+ CD5dull cells (B-1 cells) in non-NZB (black) 
and NZB (white) spleens. (#) indicates statistical significance between percentage of B-1 
cells in NZB and non-NZB. (t) indicates statistical significant difference among aging NZB. 
Error bars represent the SEM for 3 independent analyses. D, Columns represent the 
normalized RQ 2−ΔΔ CT value of miR-16 in spleens of non-NZB (black) and NZB (white) 
mice. (#) indicates significant difference in amount of miR-16 between non-NZB and NZB 
strains. In B–D, (*) indicates the ages at which NZB were treated for subsequent 
experiments. Statistical significance = p<0.05, student’s t test, two-tailed.
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Figure 2. miR-16 levels 8–9 days following in vivo lentivirus injections
A. Effect of Lentiviral injection on miR-16 levels in the plasma of NZB mice (9 mo, n = 3 
control-lenti, n=3 miR-lenti) 8 days post injection. miR-16 was determined by quantitative 
RT/PCR of RNA extracted from each sample using the standard 2−ΔΔCT method. miR-16 
expression analysis in each sample is reported relative to the expression in a control-Lenti 
NZB (control set as 1). Black columns are control-lenti values and open columns are miR-
lenti-values. Columns represent the mean and the bars are the SEM, * = statistical 
significance between miR-16 levels of NZB injected with mir15a/16-Lenti group compared 
with control-Lenti injected group (p < 0.01, student’s t test, two tailed test). B. Spleens from 
NZB treated either with mir-15a/16-lentivirus or control-lentivirus were stained with CD5, 
B220 and sorted into B-1(CD5dull, B220+) and B-2 (CD5−, B220+) and further sorted on the 
basis of GFP expression. Sorted cells were analyzed for the levels of miR-16 expression and 
columns represent the mean RQ values plus SEM. * = statistical significance between 
miR15a levels of GFP+ cells from NZB injected with miR15a/16-Lenti group compared 
with control-Lenti injected group (p < 0.05, student’s t test, two tailed test, n=3 for both 
NZB groups). C. Total B-1(CD5dull, B220+) cells in the spleen of short-term lenti-treated 
mice as a percentage of the total cells in the lymphoid gate. Columns are mean percent ± 
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SD, n=3 for both groups. D and E. Representative sorting results (at least three individual 
spleens were sorted). The percent of cells in each population is indicated on the histograms.
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Figure 3. Short-term: Flow analysis of the fate of B-1 cells
Spleen, PWC, and blood (PB) were obtained from NZB 8–9 days post-lentivirus treatment. 
A, Representative analysis of forward and side scatter (FSC and SSC) gating strategy. R1 
contains live cells, R2 contains dying, apoptotic cells. Shown is PWC following treatment 
with control lentiviral vector (left) or miR-15a/16 (right) lentivirus. B, Representative flow 
analysis of live GFP+ cells (gated on R1 and GFP) that are analyzed for IgM and CD5 
expression. The boxed area contain cells that are GFP+/IgM+/CD5+/dull C, Results from 
flow cytometric analysis of percentage of live cells (R1) gated on GFP and further analyzed 
for B-1 cells from miR-15a/16-injected NZB relative to NZB injected with control 
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lentivirus. D, Flow cytometric analysis of the ratio of the percentage of apoptotic (R2) GFP+ 
B-1 cells to live GFP+ B-1 (R1) cells is shown. Black columns = NZB injected with control 
lentivirus and white = NZB injected with miR-15a/16-expressing lentivirus. Error bars 
represent SEM (control, n = 5, and miR-15a/16 n = 8).
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Figure 4. Long-term: Flow analysis of the fate of B-1 cells
A, Representative analysis of forward and side scatter (FSC and SSC) gating strategy. R1 
contains live cells, R2 contains dying, apoptotic cells. Shown is PWC following treatment 
with control lentivirus (left) or miR-15a/16 (right) lentivirus. B, Representative flow 
analysis of live GFP+ cells (gated on R1 and GFP) that are analyzed for IgM and CD5 
expression. The boxed area contain cells that are GFP+/IgM+/CD5+/dull C, Results from 
flow cytometric analysis of percentage of live cells (R1) gated on GFP and further analyzed 
for B-1 cells from miR-15a/16-injected NZB relative to NZB injected with control 
lentivirus. (*) indicates statistical significance (student’s t-test, p<0.05). D, Flow cytometric 
analysis of the ratio of the percentage of apoptotic (R2) GFP+ B-1 cells to live GFP+ B-1 
(R1) cells is shown. Black columns = NZB injected with control lentivirus and white = NZB 
injected with miR-15a/16-expressing lentivirus. Error bars represent SEM (n = 4 for each 
group).
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Figure 5. Histopathology of NZB treated with lentivirus
Representative H&E staining (200x magnification) of spleen (top) and liver (bottom) 
sections from short-term NZB treated with control vector (left) or miR-15a/16 (right) 
lentivirus. Top: The control spleen has bulk endogenous disease with malignant 
lymphocytes (dark purple cells) invading the red and white pulps, along with a total loss in 
splenic architecture. This is markedly decreased in the miR-15a/16 treated mice. Bottom: 
The control vector-treated liver shows disease involvement with large foci forming around 
the blood vessels (indicated by arrows). These foci are lost in the miR-15a/16 treated mice.
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Figure 6. Liver functional enzyme levels
Untreated aged NZB (9–17mo) and NZB treated with control vector or miR-15a/16-
expressing lentivirus were bled at 8–9 days (short-term) or 28–29 days (long-term) and 
either serum or plasma was evaluated for levels of liver enzymes aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), as well as bilirubin 
(bili), and albumin (alb). A, Average levels of AST, ALT, ALP in U/L. B, Average levels of 
bilirubin and albumin in mg/dL and g/dL, respectively and average animal weight(g). Gray 
columns are untreated NZB, black columns are NZB injected with control lentiviral vector, 
and white columns are NZB injected with miR-15a/16 lentiviral vector. Error bars represent 
the SEM for at least 4 different mice for each group. Normal ranges for each enzyme and 
protein is indicated in the table at the bottom.
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Figure 7. Model of effects of miR-15a/16 restoration on malignant B-1 cells in vivo
A, DIRECT EFFECTS: The lentiviral vector expressing the wild-type mir-15a/16-1 
sequence integrated into a portion of B-1 cells resulting in increased miR-15a/16 expression 
and the direct death or decreased proliferation of the transduced B-1 cells due to loss of 
miR-15a/16 target gene expression (bcl-2, cyclin D1), minimal effect on other cell types. B, 
INDIRECT EFFECTS: Following mir-15a/16-lentivirus delivery, there was a decrease in 
both B-1 cells that did and did not integrate the miR-15a/16 lentiviral vector. This may be 
due to miR15a/16 secretion by the transduced malignant cells which can then be taken up by 
the non-transduced B-1 cells and subsequently mediate negative effects.
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